2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
32
Myelodysplastic Syndromes
21
Leukemia, Myelomonocytic, Chronic
12
Myeloproliferative Disorders
4
Triple Negative Breast Neoplasms
2
Myelodysplastic-Myeloproliferative Diseases
2
Leukemia, Biphenotypic, Acute
2
Anemia, Refractory, with Excess of Blasts
2
Thrombocythemia, Essential
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Patient Preference
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Neoplasms
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
GATA2 Deficiency
1
Cytopenia
1
Interventions
lutetium Lu 177 dotatate
40
Everolimus
35
Magnetic Resonance Spectroscopy
15
lanreotide
14
gallium Ga 68 dotatate
13
Temozolomide
13
Octreotide
12
Nivolumab
12
pembrolizumab
11
Capecitabine
11
surufatinib
10
177Lu-octreotide, DOTA(0)-Tyr(3)-
10
cabozantinib
9
Positron Emission Tomography Computed Tomography
9
3-Iodobenzylguanidine
9
Sunitinib
8
Specimen Handling
7
Carboplatin
7
telotristat ethyl
6
pasireotide
6
amino-acid, glucose, and electrolyte solution
6
Somatostatin
6
Lutetium-177
6
90Y-octreotide, DOTA-Tyr(3)-
6
lenvatinib
5
Ipilimumab
5
Ga(III)-DOTATOC
5
Fluorodeoxyglucose F18
5
Etoposide
5
Cisplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
decitabine and cedazuridine drug combination
×
Clear all
NCT05178693
2025-11-24
LANTana
Imperial College London
Phase 1
Recruiting
27 enrolled